EXCLUSIVE: MIRA Prescribed drugs Expands Pipeline, Enhances Worth Proposition With Improvement Of Topical Formulation For Lead Ache Therapy Candidate – Mira Prescribed drugs (NASDAQ:MIRA)

On Thursday, MIRA Prescribed drugs Inc. MIRA introduced the formulation of Ketamir-2 as a topical therapy for localized neuropathic and inflammatory ache.

The development expands the corporate’s ache administration portfolio past its ongoing Ketamir-2 oral therapy for neuropathic ache.

“The event of each an oral and topical formulation of Ketamir-2 considerably expands our pipeline and enhances the worth proposition of MIRA,” said Erez Aminov, Chairman and CEO of MIRA. “By advancing two distinct formulations, we’re positioning Ketamir-2 to handle a number of ache situations and broaden its potential purposes.”

Additionally Learn: EXCLUSIVE: MIRA Prescribed drugs Kick Begins Human Trial In Israel For Ketamir-2 For Neuropathic Ache

The topical therapy of Ketamir-2 is designed for gradual launch, delivering focused ache aid instantly on the software website whereas minimizing systemic publicity and unwanted side effects.

In contrast to present remedies—equivalent to NSAIDs, lidocaine patches, capsaicin lotions, and systemic painkillers—topical Ketamir-2 goals to offer efficient, long-lasting aid with out the dangers of systemic unwanted side effects, sedation, or opioid dependency.

MIRA is actively advancing one scientific program and a number of preclinical packages, with important milestones anticipated this yr:

• The Part 1 research for the Ketamir-2 oral therapy for neuropathic ache is advancing as deliberate, with full outcomes anticipated later this yr.
• Preclinical research are investigating Ketamir-2’s potential in treating post-traumatic stress dysfunction (PTSD), additional increasing the drug’s neuropsychiatric purposes.
• Part 2a for Diabetic Neuropathy Anticipated to Start by Yr-Finish—Preparations are underway for a Part 2a research in diabetic neuropathy sufferers, with the primary human efficacy knowledge anticipated by Q1 2026.
• A preclinical research is presently assessing the efficacy of the brand new topical formulation in treating inflammatory ache, additional increasing its potential purposes as a topical agent for persistent ache situations.
• Continued preclinical research are evaluating MIRA-55’s potential cognitive advantages.

Worth Motion: MIRA inventory traded decrease by 5% to $0.95 premarket on the final examine on Thursday.

Learn Subsequent: